CYRX · CryoPort, Inc. · Stock research

• # CYRX — Cryoport, Inc.

Current Thesis

The leg on offer is the profitability crossover at a cold-chain toll-taker on cell & gene therapy: cryogenic logistics, biostorage and MVE freezers that bill the CGT pipeline whichever therapy wins. What has changed since the last read is entirely in the tape. The 2026-08-06 Q2 print delivered revenue of $49.0M against $48.21M consensus, adjusted EBITDA from continuing operations of +$0.4M versus -$0.9M a year earlier, and FY2026 guidance affirmed at $192–196M — but the stock closed $15.12 on 2026-08-07 and went nowhere on it. Fourteen sessions later the adjusted close was $17.13 on 2026-08-21, the top of the 52-week range, RSI(14) at 67.7 against 43.5 on 2026-08-07. No company press release carries a date after 2026-08-06. The advance is the market re-rating a print it initially ignored, helped by four target raises clustered 2026-07-24 to 2026-08-07 (BTIG $17→$25, Roth $15→$21, Needham $15→$19, Guggenheim $12→$16). The unresolved fundamental — commercially approved CGT revenue growing only 9% YoY to $9.4M in Q2, down from +26% at the 2026-05-04 Q1 print — gets no dated test until the Q3 report expected in early November. Price is now above the $16.17 three-month average sell-side target reported by aggregators, and above both 2026 insider distribution prints.

Bullish and bearish views on CryoPort, Inc.

The model's bull view on CryoPort, Inc. (CYRX), in brief: Adjusted EBITDA from continuing operations turned positive at +$0.4M in Q2 2026 versus -$0.9M in Q2 2025 (press release, 2026-08-06) — a $1.3M YoY swing and the first quarter delivering the inflection management had guided toward for 2H 2026. The bear view: Commercial CGT revenue decelerated to +9% YoY ($9.4M) at the 2026-08-06 print from +26% YoY ($9.1M) at the 2026-05-04 Q1 print. Both cases follow in full.

Bull Case

• Adjusted EBITDA from continuing operations turned positive at +$0.4M in Q2 2026 versus -$0.9M in Q2 2025 (press release, 2026-08-06) — a $1.3M YoY swing and the first quarter delivering the inflection management had guided toward for 2H 2026.
• Revenue $49.0M beat the $48.21M consensus (2026-08-06); Life Sciences Services grew 15% YoY to $28.0M, led by BioStorage/BioServices +25% YoY.
• FY2026 guidance affirmed at $192–196M against $194.39M consensus (2026-08-06) — unchanged from the band set on 2026-05-04.
• Funnel widened: 779 supported global clinical trials at 2026-06-30 versus 728 at 2025-06-30, including 94 Phase 3 programmes and 22 commercially approved therapies. Management flagged up to 11 further BLA/MAA filings and five possible new approvals for the balance of 2026.
• Roth Capital's Richard Baldry raised his target to $21 from $15 with a Buy on 2026-08-07 — the fourth raise in a fortnight and the one the prior read did not have. Aggregator rating split stands at 6 buy / 1 hold.
• Cash, cash equivalents and short-term investments of $396.7M at 2026-06-30 fund the ramp without the equity market at these levels.
• The CEO's Rule 10b5-1 plan adopted 2026-05-11 was terminated on 2026-08-11 per the Form 4 covering that day's sale — the scheduled selling program is off, though nothing rules out a replacement plan.
• Price cleared the $16.57 high referenced in the 2026-08-08 read and closed at the 52-week high of $17.13 on 2026-08-21, with a three-month price change of +22.4%.

Bear Case

• Commercial CGT revenue decelerated to +9% YoY ($9.4M) at the 2026-08-06 print from +26% YoY ($9.1M) at the 2026-05-04 Q1 print. The mechanism the whole toll-taker frame rests on printed below the +15% threshold the prior read named, and nothing dated before ~November retests it.
• Life Sciences Products revenue was $21.0M, flat YoY (2026-08-06). Roughly the same segment carries the reiterated upper-single-digit FY2026 growth target, which now requires a 2H step-up with no interim datapoint.
• Adjusted EPS of -$0.20 missed the -$0.19 estimate (2026-08-06); the company remains operating-loss-making.
• The 2026-08-21 close of $17.13 sits above the $16.17 three-month average analyst target reported by aggregators. Only BTIG $25, Roth $21 and Needham $19 sit above the last close; Guggenheim's $16 sits below it.
• Both distributions cleared below the current level.
• RSI(14) 67.7 with the last close exactly at the 52-week high leaves no gap between price and the range top to absorb a disappointment.
• The advance from the 2026-08-07 close of $15.12 to 2026-08-21 came without a single dated company headline. Multiple expansion on no news reverses on no news just as easily.

Setup & Price Structure

• Reference: adjusted daily close $17.13 on 2026-08-21, 0.0% from the 52-week high on the same series. The 2026-08-07 close of $15.12 marks the pre-breakout shelf; the $16.57 level cited in the 2026-08-08 read is the pivot now underneath price.
• Momentum has fully reset: RSI(14) 67.7 versus 43.5 on 2026-08-07, still short of the 70 line. The 200-day moving average was near $11.07 when reclaimed on 2026-07-11 — far below, so the long-term trend structure is not in question at this level; the question is the extension from it.
• The narrative is maturing. Coverage has been continuous since 2026-05-22; the last company press release is dated 2026-08-06; the target-raise cluster ran 2026-07-24 to 2026-08-07 and has not extended. Price makes new highs while the headline flow has stopped — a well-known narrative still working on moderating news. It is not accelerating: no new attention event carries a date after 2026-08-07. It is not yet saturated: sell-side dispersion remains wide ($16 to $25) and no mainstream retail-sentiment wave is evidenced in the record.
• Crowding and positioning observables, stated as observables: last close at the top of the 52-week range; +22.4% over three months; price above the $16.17 aggregate target; two officer distributions in 2026 (2026-06-04 at $16.27, 2026-08-11 at $14.9092) both below the current level; a 10b5-1 plan terminated 2026-08-11 with no replacement disclosed as of this writing; and no earnings date inside 30 days, so there is no imminent print forcing positioning either way.
• What the structure does not show: any dated evidence of expanding retail participation, index inclusion, or new institutional coverage after 2026-08-07.

Catalyst Calendar (next 30 days)

• None scheduled. No company event with a confirmed date falls between 2026-08-22 and 2026-09-21. The IR calendar showed no confirmed event as of the last check, and the post-Q2 filing cycle is complete.
• ~2026-09-01 onward (est.) — EDGAR Form 4 flow. Whether a replacement Rule 10b5-1 plan appears after the 2026-08-11 termination, and at what prices, is directly observable.
• 2026-09-30 — Q3 quarter end. The supported-clinical-trial count against 779 at 2026-06-30, and commercial CGT revenue against $9.4M, are set on this date and disclosed in November.
• ~2026-11-05 (est.) — Q3 2026 earnings. The next scheduled binary: whether the +$0.4M adjusted EBITDA repeats, whether Products leaves the flat $21.0M line, and whether commercial CGT reaccelerates above +15% YoY.
• by 2026-12-31 (est.) — up to 11 possible BLA/MAA applications and five possible new therapy approvals flagged by management on 2026-08-06. Each approval converts a clinical account into higher-margin commercial volume.

What Would Change Our Mind

The breakout is the whole of what is new here — the fundamentals on the table are the same ones that printed on 2026-08-06 and produced a $15.12 close the next day. So the structure is what carries the read. Losing it means giving back the entire post-print advance: a weekly close below $15 puts price back inside the 2026-08-07 to 2026-08-11 range and leaves the 2026-08-06 print unrewarded a second time, with no scheduled event before ~2026-11-05 to change that.

Fundamentally, the case breaks on a second consecutive quarter of commercial CGT revenue growth below +15% YoY at the November print, on any cut to the affirmed $192–196M FY2026 band, or on adjusted EBITDA from continuing operations printing back below zero after the +$0.4M reported for Q2. A supported-trial count flat or lower at 2026-09-30 versus 779 would signal the funnel narrowing with the usual multi-quarter lag.

The read strengthens on the mirror image: commercial CGT back above +15% YoY, Products off the flat $21.0M line, and the FY band raised rather than affirmed. A new Rule 10b5-1 plan filed at prices materially above $17 would also change the distribution picture that has held since June.

Correlation Notes

• Demand is downstream of cell & gene therapy developer funding, so small-cap biotech risk appetite (XBI as the liquid proxy) drives the multiple more than any single company datapoint. A break of XBI's 2026 range would matter here before any Cryoport-specific number does.
• The business splits into two different correlation regimes: Life Sciences Services ($28.0M in Q2, +15% YoY) tracks trial activity and approvals; Life Sciences Products ($21.0M, flat) is a capital-equipment line exposed to biopharma capex cycles and to tariffs on cryogenic freezer manufacturing.
• Read-throughs run through CGT tooling and biostorage peers rather than freight or logistics comparables — the revenue is billed on therapy volume, not on freight rates.
• Approval-driven revenue conversion means FDA and EMA decision flow across the CGT field is a shared factor: a sector-wide slowdown in approvals compresses the mechanism management pointed to on 2026-08-06 regardless of execution.